Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Allergy Therapeutics PLC banner

Allergy Therapeutics PLC
LSE:AGY

Watchlist Manager
Allergy Therapeutics PLC Logo
Allergy Therapeutics PLC
LSE:AGY
Watchlist
Price: 10.6 GBX 6% Market Closed
Market Cap: £651m
Write Note Create Alert Ask AI
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Cash Flow Statement

Operating Cash Flow
+
3Y
-101%
5Y
-
10Y
-
Investing Cash Flow
+
3Y
+4%
5Y
-15%
10Y
-8%
Financing Cash Flow
+
3Y
-
5Y
-
10Y
+55%

Cash Flow Statement
Allergy Therapeutics PLC

Rotate your device to view
Cash Flow Statement
Currency: GBP
Jun-2005 Dec-2005 Jun-2006 Dec-2006 Jun-2007 Dec-2007 Jun-2008 Dec-2008 Jun-2009 Dec-2009 Jun-2010 Dec-2010 Jun-2011 Dec-2011 Jun-2012 Dec-2012 Jun-2013 Dec-2013 Jun-2014 Dec-2014 Jun-2015 Dec-2015 Jun-2016 Dec-2016 Jun-2017 Dec-2017 Jun-2018 Dec-2018 Jun-2019 Dec-2019 Jun-2020 Dec-2020 Jun-2021 Dec-2021 Jun-2022 Dec-2022 Jun-2023 Dec-2023 Jun-2024 Dec-2024 Jun-2025
Operating Cash Flow
Net Income
(2)
(6)
(7)
(14)
(27)
(25)
(20)
(22)
(11)
3
(0)
0
(2)
(0)
1
(2)
0
2
1
2
1
(5)
(12)
(6)
(2)
(3)
(7)
(3)
4
9
8
8
4
(5)
(13)
(28)
(50)
(57)
(39)
(36)
(39)
Depreciation & Amortization
1
1
1
1
1
1
1
1
1
1
1
1
2
2
2
2
1
1
1
1
1
1
2
2
2
2
2
2
2
3
4
4
4
4
4
4
4
4
4
4
4
Stock-Based Compensation
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
1
0
1
0
1
1
1
1
0
0
0
0
1
0
1
Other Non-Cash Items
(0)
0
0
0
1
2
6
16
6
(4)
1
1
3
1
(1)
2
2
0
(0)
0
0
(0)
0
(0)
(1)
0
1
1
1
1
1
0
(1)
0
1
1
1
3
3
6
11
Cash Taxes Paid
0
0
0
(1)
(3)
(2)
0
0
0
(0)
(1)
0
0
0
(0)
(0)
0
0
0
0
0
0
(0)
(0)
1
0
(0)
(0)
(0)
(0)
1
1
(0)
0
0
0
0
0
0
0
1
Cash Interest Paid
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
1
0
2
4
2
2
1
Change in Working Capital
2
(1)
(2)
1
8
1
(6)
(3)
4
1
(0)
(2)
(5)
1
1
(2)
(1)
(1)
0
0
(0)
0
(2)
(2)
1
0
0
(2)
(2)
0
(0)
(1)
1
(1)
(6)
(2)
8
9
(0)
(3)
(4)
Cash from Operating Activities
0
N/A
(5)
N/A
(8)
-42%
(11)
-50%
(17)
-52%
(20)
-17%
(19)
+4%
(8)
+59%
(0)
+94%
1
N/A
2
+179%
0
-80%
(2)
N/A
4
N/A
3
-24%
(1)
N/A
2
N/A
3
+26%
2
-29%
4
+76%
2
-48%
(4)
N/A
(12)
-205%
(7)
+41%
0
N/A
(0)
N/A
(4)
-1 268%
(2)
+57%
6
N/A
13
+135%
12
-5%
11
-12%
8
-24%
(1)
N/A
(14)
-1 261%
(25)
-79%
(29)
-15%
(32)
-12%
(32)
+0%
(29)
+10%
(28)
+3%
Investing Cash Flow
Capital Expenditures
(1)
(1)
(2)
(3)
(3)
(3)
(3)
(2)
(2)
(1)
(2)
(2)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(1)
(2)
(2)
(3)
(3)
(3)
(2)
(3)
(3)
(3)
(5)
(5)
(4)
(3)
(3)
(3)
Other Items
0
0
0
0
0
0
(0)
(0)
(0)
(0)
(0)
(1)
(1)
(0)
(0)
(0)
(0)
(0)
(0)
(0)
(2)
(2)
(0)
(0)
(0)
(0)
(0)
(0)
(0)
(0)
0
(0)
(0)
(0)
0
0
0
0
2
2
1
Cash from Investing Activities
(1)
N/A
(1)
-14%
(2)
-113%
(3)
-32%
(3)
-10%
(3)
+8%
(3)
+8%
(2)
+11%
(2)
+17%
(2)
+16%
(2)
-20%
(3)
-27%
(2)
+11%
(2)
+21%
(2)
+13%
(1)
+41%
(1)
-26%
(1)
-16%
(1)
+16%
(1)
+10%
(3)
-161%
(3)
-6%
(1)
+47%
(2)
-55%
(2)
+16%
(2)
+18%
(3)
-57%
(2)
+9%
(3)
-48%
(4)
-5%
(3)
+29%
(2)
+10%
(3)
-16%
(3)
-16%
(3)
+2%
(5)
-56%
(5)
+2%
(4)
+23%
(1)
+66%
(1)
+32%
(3)
-253%
Financing Cash Flow
Net Issuance of Common Stock
16
1
19
19
0
0
0
0
0
24
26
2
0
0
13
13
0
0
0
0
20
31
11
0
0
0
0
10
11
0
0
0
0
0
0
6
6
40
2
(37)
0
Net Issuance of Debt
(1)
0
0
0
3
14
19
8
0
(20)
(19)
0
2
(1)
(15)
(10)
0
0
0
0
0
(0)
2
2
(0)
(0)
(0)
(1)
(1)
(1)
(0)
0
(2)
(2)
(2)
(2)
24
(2)
33
78
33
Other
(1)
(1)
(0)
0
0
0
0
0
0
0
(2)
(3)
(1)
(1)
(0)
0
0
0
0
0
0
0
0
0
0
0
0
0
(0)
(0)
(0)
(0)
(0)
(0)
(1)
(1)
(2)
(4)
(4)
(3)
(2)
Cash from Financing Activities
14
N/A
0
-100%
19
+61 667%
19
0%
3
-85%
14
+404%
19
+37%
8
-59%
0
-99%
3
+3 230%
5
+47%
(1)
N/A
1
N/A
(2)
N/A
(3)
-21%
3
N/A
0
-95%
0
N/A
0
N/A
0
N/A
20
+66 830%
31
+54%
13
-59%
2
-87%
(0)
N/A
(0)
-30%
(0)
-20%
10
N/A
10
-1%
(1)
N/A
(0)
+68%
(0)
+67%
(2)
-1 332%
(3)
-36%
(3)
-1%
4
N/A
28
+678%
34
+23%
31
-8%
38
+21%
31
-18%
Change in Cash
Effect of Foreign Exchange Rates
0
0
0
0
0
0
0
0
0
0
(0)
0
0
(0)
(0)
0
0
(0)
(0)
(0)
(0)
1
3
2
1
0
0
0
0
(0)
(0)
(0)
(0)
(0)
0
0
0
(0)
(0)
0
(0)
Net Change in Cash
14
N/A
(6)
N/A
9
N/A
4
-51%
(18)
N/A
(9)
+46%
(3)
+64%
(3)
+19%
(2)
+15%
2
N/A
5
+100%
(3)
N/A
(3)
-16%
(0)
+91%
(1)
-345%
2
N/A
1
-5%
2
+15%
1
-43%
3
+188%
19
+595%
25
+32%
2
-91%
(5)
N/A
(1)
+76%
(2)
-52%
(7)
-237%
6
N/A
12
+104%
8
-32%
10
+18%
9
-10%
3
-61%
(7)
N/A
(20)
-186%
(26)
-33%
(6)
+78%
(2)
+70%
(2)
-15%
8
N/A
(0)
N/A
Free Cash Flow
Free Cash Flow
(0)
N/A
(6)
-1 374%
(10)
-54%
(15)
-50%
(20)
-39%
(23)
-14%
(22)
+5%
(10)
+54%
(2)
+79%
(1)
+66%
0
N/A
(1)
N/A
(3)
-179%
2
N/A
2
-28%
(1)
N/A
2
N/A
2
+30%
1
-40%
3
+142%
1
-70%
(5)
N/A
(13)
-152%
(9)
+30%
(2)
+83%
(2)
-6%
(6)
-265%
(4)
+41%
3
N/A
10
+290%
10
+2%
9
-12%
6
-34%
(4)
N/A
(17)
-322%
(30)
-75%
(34)
-12%
(36)
-7%
(36)
+1%
(32)
+10%
(32)
+2%

See Also

Summary
AGY intrinsic value, competitors valuation, and company profile.
DCF Valuation
AGY stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AGY stock valuation using valuation multiples.
Wall Street Estimates
AGY price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AGY stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Follow us
Join more than 319,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.